<DOC>
	<DOCNO>NCT03076892</DOCNO>
	<brief_summary>This study aim compare efficacy tolerance new photodynamic therapy device ( PHOS-ISTOS ) conventional PDT device ( Aktilite® ) treatment actinic keratosis scalp</brief_summary>
	<brief_title>Evaluation Non-inferiority Tolerability Device PHOS-ISTOS</brief_title>
	<detailed_description>The study intraindividual comparison two method . The number subject enrolled 47 . Patients receive treatment single visit : A first period 2.5 hour illumination Phos-Istos device follow continuous red light spectrum ( 7 10 minute ) Aktilite® appropriate incubation MAL ( methyl aminolevulinate ) . Patients complete pain assessment scale receiving treatment . 3 follow-up visit schedule</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Clinical diagnosis minimum 10 previously untreated pigment , nonhyperkeratotic AK lesion Grade I II forehead and/or scalp ( accord Olsen et Al . JAAD 1991 , cf . REF 31 ) therapy unacceptable consider medically less appropriate symmetrical repartition side forehead and/or scalp . The diagnosis AK determine upon clinical evaluation ( i.e . visual inspection palpation ) investigator . No treatment AKs previous 3 month . Symmetrical area term number severity lesion . The axis symmetry two area define investigator accord distribution lesion . The two area treat coalesce . A minimum distance 10 mm require lesion locate 2 symmetrical area . A minimum distance 2 mm require lesion side . Minimum 5 lesion similar dimension symmetrical area treat . If number lesion &gt; 7 , 7 lesion side consider . Patients porphyria . Patients immunosuppressed idiopathic , disease specific therapeutic reason . Use topical corticosteroid lesional area within 2 week PDT . Patients receive local treatment ( include cryotherapy curettage , PDT treatment ) face / scalp area within last 30 day . Patients receive topical treatment ( include imiquimod , 5FU diclofenac , Picato ) face / scalp area within last 30 days.in Use topical retinoids alphahydroxy acid , systemic retinoids , chemotherapy immunotherapy within 4 week PDT . Pigmented AK lesion ( ) . Known allergy Metvixia/Metvix , similar PDT compound excipients cream include arachis oil , peanut soya . Participation clinical study either currently within last 30 day . Female subject must either : Nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus ) , Childbearing potential , provide confirm negative urine pregnancy test prior study treatment , rule pregnancy . Any condition may associate risk poor protocol compliance . Patients currently receive regular ultraviolet radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDT</keyword>
	<keyword>Methyl Aminolevulinate</keyword>
	<keyword>light emit textile</keyword>
</DOC>